After completing my PhD in Oncology at the Aix-Marseille University in 2006, I joined the Tumour Biology and Targeting Program led by Maria Kavallaris at the Children's Cancer Institute (Sydney, Australia), where I spent 7.5 years as post-doctoral researcher and junior group leader. In 2014, I was awarded a Marie Sklodowska-Curie Fellowship from the European Research Council, which allowed me to come back to France and become a member of the Center for Research in Oncobiology and Oncopharmacology (INSERM U911 – Marseille). Finally, I joined the iSCB group in October 2016 when I was recruited by the CNRS as a permanent researcher (CR1).
My project aims at identifying and validating novel therapeutic targets in refractory cancers by combining high-throughput screening and chemogenomic technologies. My research focuses on pharmacology (i.e. anti-cancer agents and drug repurposing) and functional genomics. I'm particularly interested in hard-to- treat cancers such as neuroblastoma, glioblastoma, angiosarcoma and acute leukaemias.
- 2016 – Pasquier E*, André N, Street J, Chougule A, Rekhi B, Ghosh J, Philip DS, Meurer M, MacKenzie KL, Kavallaris M and Banavali S. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. EBioMedicine, 6: 87-95 – corresponding author
- 2015 – Pasquier E, Tuset MP, Sinnappan S, Carnell M, Macmillan A and Kavallaris M. γ-Actin plays a key role in endothelial cell motility and neovessel maintenance. Vascular Cell, 6 (7): 2.
- 2014 – André N, Carré M and Pasquier E*. Metronomics: towards personalized chemotherapy? Nature Reviews Clinical Oncology, 11 (7): 413-31 – corresponding author
- 2014 – Brandl MB, Pasquier E, Li F, Beck D, Zhang S, Zhao H, Kavallaris M and Wong ST. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer. Molecular Oncology, 8 (8): 1548-60.
- 2013 – Pasquier E*, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris M, Trahair T, Andre N and Kavallaris M. Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma. British Journal of Cancer, 108 (12): 2485-94 – corresponding author
- 2013 – McGuire MF, Enderling H, Wallace DI, Batra J, Jordan M, Kumar S, Panetta JC and Pasquier E*. Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. Cancer Research, 73 (20): 6111-7 – corresponding author
- 2013 – Pasquier E, Tuset MP, Street J, Sinnappan S, MacKenzie KL, Braguer D, Andre N and Kavallaris M. Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis, 16 (2): 373-86.2013 – André N, Banavali S, Snihur Y and Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncology, 14 (6): e239-48.
- 2011 – Pasquier E*, Ciccolini C, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M and Andre N. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget, 2 (10): 797-809 – corresponding author
- 2010 – Pasquier E, Sinnappan S, Munoz M and Kavallaris M. ENMD-1198, a new analog of 2-methoxyestradiol, displays both anti-angiogenic and vascular-disrupting properties. Molecular Cancer Therapeutics, 9 (5): 1408-18.
- 2010 – Pasquier E*, Kavallaris M and André N. Metronomic chemotherapy: New rationale for new directions. Nature Reviews Clinical Oncology, 7 (8): 455-65 – corresponding author